title: Icotinib as initial treatment in lung adenocarcinoma patients with brain metastases.
abstract: BACKGROUND
  To evaluate the antitumor activity and toxicity of icotinib as initial treatment in lung adenocarcinoma patients with brain metastases.
  
  
  METHODS
  Twenty-one patients with histologically or pathologically documented brain metastatic lung cancer were administered icotinib as initial treatment from 2011 to 2015 at the Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Chemotherapy response was assessed by Response Evaluation Criteria in Solid Tumors and toxicity was evaluated according to National Cancer Institute-Common Toxicity Criteria. Icotinib was administered three times per day at a dose of 125mg.
  
  
  RESULTS
  The median overall and progression-free survival rates were 15.2 (1.2-31.5 months, 95% confidence interval [CI] 6.6-23.7 months) and 8.9 months (0.6-30.5 months, 95% CI 3.4-14.3 months), respectively. The overall response and disease control rates were 61.9% and 90.5%, respectively. Icotinib was well tolerated, and no grade 3/4 adverse events were observed. The most common grade 1/2 adverse events included acneiform eruptions (38.1%), diarrhea (19.0%), and stomatitis (9.5%).
  
  
  CONCLUSIONS
  Icotinib is effective and well tolerated as initial treatment in lung adenocarcinoma patients with brain metastases.
authors.affiliation: Department of Medical Oncology Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College Beijing China.
authors.forename: Jian-Ping
authors.initials: JP
authors.lastname: Xu
authors.affiliation: Department of Medical Oncology Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College Beijing China.
authors.forename: Xiao-Yan
authors.initials: XY
authors.lastname: Liu
authors.affiliation: Department of Medical Oncology Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College Beijing China.
authors.forename: Sheng
authors.initials: S
authors.lastname: Yang
authors.affiliation: Department of Medical Oncology Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College Beijing China.
authors.forename: Chang-Gong
authors.initials: CG
authors.lastname: Zhang
authors.affiliation: Department of Medical Oncology Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College Beijing China.
authors.forename: Lin
authors.initials: L
authors.lastname: Wang
authors.affiliation: Department of Medical Oncology Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College Beijing China.
authors.forename: Yuan-Kai
authors.initials: YK
authors.lastname: Shi
keywords: Brain metastasis; icotinib; lung adenocarcinoma; targeted therapy